Eliem Therapeutics, Inc. (ELYM)

NASDAQ: ELYM · IEX Real-Time Price · USD
3.04
-0.05 (-1.62%)
Oct 4, 2022 4:30 PM EDT - Market closed
-1.62%
Market Cap 80.77M
Revenue (ttm) n/a
Net Income (ttm) -49.28M
Shares Out 26.57M
EPS (ttm) -2.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,900
Open 3.02
Previous Close 3.09
Day's Range 3.00 - 3.28
52-Week Range 2.52 - 20.91
Beta n/a
Analysts Buy
Price Target 6.12 (+101.3%)
Earnings Date Sep 12, 2022

About ELYM

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical ... [Read more...]

Industry Biotechnology
IPO Date Aug 10, 2021
Employees 41
Stock Exchange NASDAQ
Ticker Symbol ELYM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ELYM stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 101.32% from the latest price.

Price Target
$6.12
(101.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022

1 month ago - GlobeNewsWire

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Shares of Eliem Therapeutics Inc. ELYM, -11.51% tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain after...

2 months ago - Market Watch

Eliem Therapeutics Provides ETX-810 Program Update

Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued Phase 2a clinical trial of ETX-810 in lumbosacral radic...

2 months ago - GlobeNewsWire

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023

2 months ago - GlobeNewsWire

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neurona...

2 months ago - GlobeNewsWire

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral ...

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022

3 months ago - GlobeNewsWire

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: REVTHCATXMDWEBR
3 months ago - Benzinga

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The...

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: TXMDBEEMISIGJOAN
3 months ago - Benzinga

Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop

Short squeeze stocks are once again in focus this week as the bears continue to run wild in the stock market. The post Short Squeeze Stocks: VTNR, VERU and 3 Others Experts Think Are Ready to Pop appear...

Other symbols: VERUVTNRCWHMDVL
4 months ago - InvestorPlace

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain El...

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: CWHVTNRMDVLVERU
4 months ago - Benzinga

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc.  (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neurona...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eliem Therapeutics, Inc. - ELYM

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Eliem Therapeutics, Inc. ("Eliem" or the "Company") (NASDAQ: ELYM). Such investors ar...

4 months ago - Newsfile Corp

Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Eliem Therapeutics, Inc. (ELYM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme...

4 months ago - Zacks Investment Research

Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic

Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data.

5 months ago - GeekWire

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically significant separation from placebo on the trial's primary e...

5 months ago - Benzinga

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint

5 months ago - GlobeNewsWire

Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuron...

5 months ago - GlobeNewsWire

Eliem Therapeutics to Present at Stifel's 2022 CNS Days

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuron...

6 months ago - GlobeNewsWire

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022

6 months ago - GlobeNewsWire

Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neurona...

7 months ago - GlobeNewsWire

Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neurona...

7 months ago - GlobeNewsWire

Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones

ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) is fully enrolled

8 months ago - GlobeNewsWire

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive dis...

10 months ago - GlobeNewsWire

Eliem Therapeutics to Participate at Four Upcoming Investor Conferences

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability ...

11 months ago - GlobeNewsWire

Eliem Therapeutics Reports Second Quarter Financial Results

On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months

1 year ago - GlobeNewsWire